|
|||
|
Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
Yankai Xu, Ruihua Liu, Chu Liu, Yuanshan Cui, Zhenli Gao
Int Neurourol J. 2017;21(3):212-219. Published online 2017 Sep 12
DOI: https://doi.org/10.5213/inj.1734934.467 |
|||
|
Citations to this article as recorded by  A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
Shailendra Kumar, Vidushi Tiwari, Dileep K Chaurasia, Sudheer Kumar, Shirish Mishra
Cureus.2023;[Epub] CrossRef Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double‐blind, randomized placebo‐controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study)
Sung Yong Cho, Seong Jin Jeong, Sangchul Lee, Janghwan Kim, Seong Ho Lee, Min Soo Choo, Seung‐June Oh
Neurourology and Urodynamics.2021; 40(1): 286. CrossRef Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy
Tong Cai, Ning Wang, Liye Liang, Zhongbao Zhou, Yong Zhang, Yuanshan Cui
International Neurourology Journal.2020; 24(4): 365. CrossRef Effectiveness and persistence of mirabegron as a first‐line treatment in patients with overactive bladder in real‐life practice
Jung Hyun Shin, Myung‐Soo Choo
LUTS: Lower Urinary Tract Symptoms.2019; 11(3): 151. CrossRef
|
